Phase 1-2 Study of MDV3100 in Prostate Cancer

We are conducting an ongoing Phase 1-2 clinical trial of our novel androgen receptor antagonist, MDV3100, in patients with castration-resistant (also known as hormone refractory) prostate cancer. Study highlights:

• Open-label dose-escalation study enrolling prostate cancer patients who have failed standard hormonal therapies

For more information on MDV3100 study locations, eligibility and enrollment, please click here.